← ANALYST RATINGS · TIPRANKS
Madrigal Pharmaceuticals (MDGL): analyst forecast and price target
Analyst consensus
Strong Buy11 Buy1 Hold0 Sell
Ratings of 12 analysts in the last 3 months12-month forecast
Based on 12 price targets given in the last 3 months, the average target is $684, the highest $962, the lowest $543. The average is +52.2% from the last price of $450.
Analyst ratings 19
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Ashwani Verma★★★★★★★★★★#1305 · hits 60% · avg +13.4% | UBS | $669 → $735+9.9% | Buy | +63.4% | Reiterated | 14.10.26on TipRanks 07:11 | +2.8%next day −0.3% | ↗ |
| Sadia Rahman★★★★★★★★★★#5292 · hits 70% · avg +11.8% | Wells Fargo | $685 | Buy | +52.3% | Reiterated | 12.10.26on TipRanks 07:00 | −0.9%next day −3.2% | ↗ |
| Andrew Fein★★★★★★★★★★#267 · hits 52% · avg +23.7% | H.C. Wainwright | $620 | Buy | +37.9% | Reiterated | 08.10.26on TipRanks Oct 9 08:01 | −1.8%next day −1.7% · 5 days −3.3% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $563 → $505−10.3% | Hold | +12.3% | Reiterated | 08.10.26on TipRanks 14:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $560 → $512−8.6% | Hold | +13.8% | Reiterated | 08.10.26on TipRanks 14:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $546 → $485−11.2% | Hold | +7.8% | Reiterated | 08.10.26on TipRanks 14:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $544 → $493−9.4% | Hold | +9.6% | Reiterated | 08.10.26on TipRanks 14:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $576 → $524−9.0% | Hold | +16.5% | Reiterated | 08.10.26on TipRanks 14:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $595 → $522−12.3% | Hold | +16.1% | Reiterated | 08.10.26on TipRanks 14:05 | — | |
| Eliana Merle★★★★★★★★★★#4163 · hits 45% · avg +3.0% | Barclays | $962 | Buy | +113.9% | Reiterated | 30.09.26on TipRanks 05:25 | −0.9%next day −1.0% · 5 days −5.1% | ↗ |
| Andrea Newkirk★★★★★★★★★★#2841 · hits 50% · avg +29.4% | Goldman Sachs | $704 | Buy | +56.5% | Initiated | 24.09.26on TipRanks 04:30 | +0.1%next day +0.1% · 5 days −2.2% | ↗ |
| Eric Joseph★★★★★★★★★★#1258 · hits 52% · avg +11.4% | Citi | $725 | Buy | +61.2% | Initiated | 23.09.26on TipRanks 05:15 | −0.4%next day +0.1% · 5 days −1.1% | ↗ |
| Edward Nash★★★★★★★★★★#204 · hits 52% · avg +29.5% | Canaccord Genuity | $612 | Buy | +36.1% | Reiterated | 11.08.26on TipRanks Aug 12 07:20 | +4.2%next day −0.1% · 5 days −1.6% | ↗ |
| Andy Chen★★★★★★★★★★#959 · hits 67% · avg +28.8% | Wolfe Research | $605 | Buy | +34.5% | Upgrade | 04.08.26on TipRanks 05:32 | +3.5%next day +1.5% · 5 days +5.6% | ↗ |
| Unknown Analyst | B. Riley Securities | $670 | Buy | +49.0% | Initiated | 31.07.26on TipRanks 10:06 | −6.0%next day +1.7% · 5 days +5.6% | ↗ |
| Srikripa Devarakonda★★★★★★★★★★#200 · hits 62% · avg +26.3% | Truist Financial | $709 | Buy | +57.6% | Reiterated | 31.07.26on TipRanks 07:40 | −6.0%next day +1.7% · 5 days +5.6% | ↗ |
| Jason Zemansky★★★★★★★★★★#467 · hits 60% · avg +21.6% | Bank of America Securities | $553 → $543−1.8% | Hold | +20.7% | Reiterated | 30.07.26on TipRanks Jul 31 06:05 | −11.5%next day −6.0% · 5 days −0.1% | ↗ |
| Ritu Baral★★★★★★★★★★#49 · hits 58% · avg +46.9% | TD Cowen | $644 | Buy | +43.2% | Reiterated | 30.07.26on TipRanks Jul 31 03:46 | −11.5%next day −6.0% · 5 days −0.1% | ↗ |
| Jonathan Wolleben★★★★★★★★★★#249 · hits 53% · avg +23.6% | Citizens JMP | $737 → $739+0.3% | Buy | +64.3% | Reiterated | 17.07.26on TipRanks 05:25 | +2.4%next day −3.1% · 5 days −1.0% | ↗ |
| Unknown Analyst | Jefferies | $600 | Buy | +33.4% | Reiterated | 30.06.26on TipRanks Jul 6 21:01 | +1.1%next day −4.1% · 5 days +5.5% | ↗ |
| Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% | Piper Sandler | $900 | Buy | +100.1% | Reiterated | 29.06.26on TipRanks 07:40 | +1.2%next day +1.1% · 5 days +2.5% | ↗ |
| Michael DiFiore★★★★★★★★★★#10315 · hits 56% · avg −8.0% | Evercore ISI | $652 → $649−0.5% | Buy | +44.3% | Reiterated | 07.05.26on TipRanks 08:10 | −0.6%next day −5.5% · 5 days −1.3% | ↗ |
| Kaveri Pohlman★★★★★★★★★★#1640 · hits 40% · avg +12.9% | Clear Street | $533 → $680+27.6% | Buy | +51.2% | Reiterated | 06.05.26on TipRanks 17:05 | −0.6%next day −5.5% · 5 days −1.3% | ↗ |
| Jay Olson★★★★★★★★★★#301 · hits 48% · avg +24.9% | Oppenheimer | $650 | Buy | +44.5% | Reiterated | 09.02.26on TipRanks Feb 18 12:05 | +1.8%next day −1.7% · 5 days +1.4% | |
| Prakhar Agrawal★★★★★★★★★★#1817 · hits 40% · avg +16.0% | Cantor Fitzgerald | — | Buy | — | Upgrade | 04.11.25on TipRanks 16:20 | +6.7%next day +3.7% · 5 days +10.3% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Madrigal Pharmaceuticals
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 09.10.26: target $684 at a price of $477 (+43.3%); now: $684 at $450 (+52.2%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 4 | 5 | 5 | 4 | 3 |
| Buy | 11 | 11 | 19 | 12 | 13 | 6 |
| Hold | 2 | 3 | 5 | 4 | 3 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.83 (from $-2.00 to $-0.10). Last quarter: $-1.99.
Sales
Next quarter’s sales estimate — $405M (from $385M to $422M). Last quarter: $364M.
Best top-analyst consensus in the sector · Healthcare
About Madrigal Pharmaceuticals
- CEO: William J. Sibold
- Employees: 915
- 1001 Conshohocken State Road, West Conshohocken, PA, 19428, US
- www.madrigalpharma.com
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Data from the stock’s TipRanks forecast page, read 12 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗